Research Paper Volume 15, Issue 12 pp 5650—5661

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma


Figure 3. Prognostic analysis of the immune prognostic model (IPM). Kaplan-Meier curves of the difference in overall survival (OS) between high- and low-risk cases in (AF) the whole The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts, (B) mucin 16 wild-type (MUC16WT) subgroup, and (C) mucin 16 mutation (MUC16MUT) subgroup. (DG) Relationship between risk score (upper) and expression of two prognostic immune genes (bottom). (EH) Time-dependent receiver operating characteristic (ROC) curve analysis of the IPM.